Moderna’s work developing seasonal vaccines is ‘risky’ under current FDA, analyst says
The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.
Last updated: 2026-02-12 02:08:28 ET
The biotech company said the FDA won’t review its flu vaccine, in the latest hit to mRNA development.
Shares of biotech company CSL plunged after the company announced that Chief Executive Officer Paul McKenzie will step down.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
Amgen is having a moment. The biotech bellwether is trading near fresh 52-week highs, up roughly 8% in the latest session, and the tape is sending ...